
|Articles|February 24, 2010
VEGF Trap-Eye shows positive results in a phase 2 study in patients with diabetic macular oedema
VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
2
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











